logo
Share SHARE
FONT-SIZE Plus   Neg

AstraZeneca Says US District Court Finds SEROQUEL XR Formulation Patent As Valid

AstraZeneca Plc (AZN: Quote,AZN.L) said Thursday that the US District Court for the District of New Jersey has found the formulation patent protecting SEROQUEL XR (quetiapine fumarate) extended release tablets to be valid.

According to the company, the court has ruled that Anchen Pharmaceuticals Inc., Osmotica Pharmaceutical Corp., Torrent Pharmaceuticals Limited, Torrent Pharma Inc., Mylan Pharmaceuticals Inc., and Mylan Inc. (MYL) have infringed the SEROQUEL XR formulation patent. The SEROQUEL XR formulation patent expires in 2017.

The decision follows a ruling made in the UK on March 22, 2012, which found the formulation patent protecting SEROQUEL XR to be invalid. In the Netherlands, however, on March 7, 2012, the District Court in The Hague found the formulation patent protecting SEROQUEL XR to be valid.

AstraZeneca said it is pleased with the US District Court's decision, which the company believes underlines the strength of its patents.

Seroquel generated $5.83 billion in global sales last year, with $1.4 billion coming from Seroquel XR.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Electronic Arts Inc. (EA) on Tuesday reported an increase in profit for the fourth quarter, reflecting continued strong demand from gamers for titles compatible with new-gen consoles and better digital revenues, with both earnings and revenues topping Wall Street estimates. Redwood City, California-based... Daily deals site Groupon Inc said Tuesday after the markets closed that its first quarter loss narrowed from last year, as revenue increased and operating expenses fell. The company's quarterly earnings per share, excluding item, also came in above analysts' expectations, but its quarterly revenue fell short of analysts' forecast. Mylan reported a plunge in profit, hurt by acquisition costs and a stronger dollar. However, quarterly earnings topped Wall Street estimates, while sales missed expectations despite growth across all regions.
comments powered by Disqus
Follow RTT